Laura J Bloem
Research Associate Professor, Pharmaceutical Sciences
Associate Director UICentre, UIC
Contact
Address:
833 S Wood Street, Chicago, Illinois
Office Phone:
Email:
Related Sites:
About Heading link
Overview:
I am a biochemist/molecular biologist by training and through my career have used this skill set in both academic and pharma/biotech environments. For more than 15 years I refined and utilized my biochemical and molecular skills in the pharmaceutical industry. My work in this sector focused on targeted drug discovery in oncology and cardiovascular disease at Eli Lilly and Company. I served as Kinase Platform leader in the Quantitative Biology (QB)/Screening group where I oversaw development and support of cell-based and biochemical assays for all kinase targets. I worked closely with medicinal chemists and biologists to establish screening strategies, develop project plans and set timelines to meet project goals and manage QB resources. As QB point person for external collaborations I oversaw compound testing for kinase projects at contract research organizations (CROs) in Europe, Asia and the US, establishing the strategy, setting appropriate milestones, tracking budgets and ensuring compliance for material and data transfer and quality standards. My years of experience and expertise in drug discovery assay development makes me ideally suited to add this dimension to translational research programs in the academic setting. In my current role as a Research Associate Professor for UICentre, I work closely with PI’s at UIC to identify, develop and validate bioassays for targets and pathways of interest. These assays are subsequently used for chemical probe and drug discovery efforts in collaboration with the medicinal chemistry teams at UIC
Teaching and Supervision Heading link
Selected Grants
Development of Small Molecule Inhibitors of G12 / Alpha-SNAP-dependent vWF Secretion, Chicago Biomedical Consortium., 10/1/2021 - 12/31/2024, Obligated Amount: $250000; Anticipated Amount: $250000
Development of GCN2 inhibitors to potentiate the activity of asparaginases, US Dept of Veterans Affairs (Medical Research Ser)., 8/15/2020 - 8/14/2021, Obligated Amount: $40000; Anticipated Amount: $40000
Selected Publications
Nair, Rakesh Sathish, Kumar, Sandeep, Das, Subhasis, Singh, Sunil Kumar, Srivastava, Piush, Sondarva, Gautam, Rao, Arundhati, Sinha, Subhash C, Xiong, Rui, Bloem, Laura, Hoskins, Kent, Thatcher, Gregory RJ, Rana, Basabi, Rana, Ajay. (2023). TrkA expression directs the anti-neoplastic activity of MLK3 inhibitors in triple-negative breast cancer. Oncogene, 42, (14), 1132-1143. doi:10.1038/s41388-023-02633-6.
Ahmed, Emaad, Abdulridha, Zahir, Hartmanis, Nick, Gilchrist, Annette, Layden, Brian, Bloem, Laura. (2021). Investigation of the free fatty acid receptor 2 and its role in the treatment of type 2 diabetes mellitus. The FASEB Journal, 35, (S1). doi:10.1096/fasebj.2021.35.s1.02140.
Pérez Morales, Tiara G, Ratia, Kiira, Wang, Duo-Sheng, Gogos, Artemis, Bloem, Laura, Driver, Tom G, Federle, Michael J. (2018). A novel chemical inducer of Streptococcus quorum sensing acts by inhibiting the pheromone-degrading endopeptidase PepO.. Journal of Biological Chemistry, 293, (12), 4580. doi:10.1074/jbc.aac118.002674.
Pérez Morales, Tiara G, Ratia, Kiira, Wang, Duo-Sheng, Gogos, Artemis, Bloem, Laura, Driver, Tom G, Federle, Michael J. (2018). A novel chemical inducer of Streptococcus quorum sensing acts by inhibiting the pheromone-degrading endopeptidase PepO. Journal of Biological Chemistry, 293, (3), 931-940. doi:10.1074/jbc.m117.810994.
Smith, Michele C, Mader, Mary M, Cook, James A, Iversen, Philip, Ajamie, Rose, Perkins, Everett, Bloem, Laura, Yip, Yvonne Y, Barda, David A, Waid, Philip P, Zeckner, Douglas J, Young, Debra A, Sanchez-Felix, Manuel, Donoho, Gregory P, Wacheck, Volker. (2016). Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth. Molecular Cancer Therapeutics, 15, (10), 2344-2356. doi:10.1158/1535-7163.mct-15-0996.
Ma, L, Clayton, JR, Walgren, RA, Zhao, B, Evans, RJ, Smith, MC, Heinz-Taheny, KM, Kreklau, EL, Bloem, L, Pitou, C, Shen, W, Strelow, JM, Halstead, C, Rempala, ME, Parthasarathy, S, Gillig, JR, Heinz, LJ, Pei, H, Wang, Y, Stancato, LF, Dowless, MS, Iversen, PW, Burkholder, TP. (2013). Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F. Blood Cancer Journal, 3, (4), e109-e109. doi:10.1038/bcj.2013.6.
Bose, Suchira, Cavallini, Annalisa, Murray, Tracey, Baschirotto, Lisa, Czilli, Dan, Cella, Claire, Ward, Mark, Hanmer, Jenna, Sims, Helen, Eberle, Elizabeth, Simmons, Aaron, Sossick, Sandra, Cramer, Jeff, Calligaro, David, Mateo, Ana, Bloem, Laura, Nuthall, Hugh, O’Neill, Michael, Davies, Peter, Goedert, Michel, Hutton, Michael, Szekeres, Philip. (2012). P3‐025: Chronic inhibition of the MEK/ERK pathway fails to delay disease progression in a transgenic animal model of tauopathy. Alzheimer’s & Dementia, 8, (4S_Part_13), p463-p463. doi:10.1016/j.jalz.2012.05.1243.
Burkholder, Timothy P, Clayton, Joshua R, Rempala, Mark E, Henry, James R, Knobeloch, John M, Mendel, David, McLean, Johnathan A, Hao, Yan, Barda, David A, Considine, Eileen L, Uhlik, Mark T, Chen, Yuefeng, Ma, Liandong, Bloem, Laura J, Akunda, Jacqueline K, McCann, Denis J, Sanchez-Felix, Manuel, Clawson, David K, Lahn, Michael M, Starling, James J. (2012). Erratum to: Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model. Investigational New Drugs, 30, (3), 1270-1271. doi:10.1007/s10637-011-9684-7.
Burkholder, Timothy P, Clayton, Joshua R, Rempala, Mark E, Henry, James R, Knobeloch, John M, Mendel, David, McLean, Johnathan A, Hao, Yan, Barda, David A, Considine, Eileen L, Uhlik, Mark T, Chen, Yuefeng, Ma, Liandong, Bloem, Laura J, Akunda, Jacqueline K, McCann, Denis J, Sanchez-Felix, Manuel, Clawson, David K, Lahn, Michael M, Starling, James J. (2012). Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model. Investigational New Drugs, 30, (3), 936-949. doi:10.1007/s10637-011-9640-6.